Edgar Filing: ENDOCYTE INC - Form 4

ENDOCYTE	E INC										
Form 4 February 08,	2016										
	_									OMB A	PROVAL
FORM	UNITED	STATES		ATTIES A				IGE C	COMMISSION	OMB Number:	3235-0287
Check thi if no long subject to Section 1 Form 4 o Form 5 obligation may cont <i>See</i> Instru 1(b).	suant to S	F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Section 16(a) of the Securities Exchange Act of 1934, Public Utility Holding Company Act of 1935 or Section of the Investment Company Act of 1940							January 31 Expires: 2005 Estimated average burden hours per response 0.5		
(Print or Type F	Responses)										
1. Name and A Ellis P Ron	ddress of Reporting F	Person <u>*</u>	Symbol	Name and			ding	2	5. Relationship of Issuer		
(Last)	(First) (N	(Check all applicable)				;)					
3000 KENT	AVE, STE A1-1	00	(Month/D 02/04/20	-					X Director X Officer (give below) Presi		Owner er (specify
	(Street)			ndment, Da hth/Day/Yea	-	nal			6. Individual or Jo Applicable Line) _X_ Form filed by 0		
WEST LAF	AYETTE, IN 479	006							Form filed by M Person		
(City)	(State)	(Zip)	Table	e I - Non-I	Derivativ	ve Secu	urit	ies Acq	uired, Disposed of	, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	urity (Month/Day/Year) Execution Date, if Transaction(A) or Dispo any Code (Instr. 3, 4 ar (Month/Day/Year) (Instr. 8)		sposed of (D)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)					
Common	02/04/2016			Code V A	26,87	int (1	or D)	Price \$ 0	(Instr. 3 and 4) 336,356 (2)	D	
Stock Common Stock	02/04/2016			F	(1) 3,320 (3)	D)	\$ 3.18	333,036	D	
Common Stock	02/06/2016			F	2,085 (4)	D)	\$ 3.02	330,951	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

Edgar Filing: ENDOCYTE INC - Form 4

number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 3.18	02/04/2016		А	161,250	(5)	02/04/2026	Common Stock	161,250

Reporting Owners

Reporting Owner Name / Address		R	elationships	
	Director	Director 10% Owner Officer		Other
Ellis P Ron 3000 KENT AVE, STE A1-100 WEST LAFAYETTE, IN 47906	Х		President and CEO	
Signaturaa				

Signatures

/s/ Michael A. Sherman, Attorney-in-fact for P. Ron Ellis (power of attorney previously 02/08/2016 filed)

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents restricted stock units that will vest and be paid 1/4 annually over a period of 4 years beginning on February 4, 2017, in the form of one share of common stock for each restricted stock unit.
- (2) Includes 2,617 and 1,668 shares acquired under the Endocyte, Inc. 2010 Employee Stock Purchase Plan on June 15, 2015 and December 15, 2015, respectively.
- (3) Represents shares withheld to satisfy tax withholding obligations associated with the settlement of 8,959 restricted stock units in the form of Company common stock on a one-for-one basis on February 4, 2016.
- (4) Represents shares withheld to satisfy tax withholding obligations associated with the settlement of 5,625 restricted stock units in the form of Company common stock on a one-for-one basis on February 6, 2016.
- (5) Shares subject to the option vest 1/4 annually over a period of 4 years beginning on February 4, 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Date